Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Database

ABPEPserver: a web application for documentation and analysis of substitutants

Authors: Abhijeet Pataskar, Jasmine Montenegro Navarro, Reuven Agami

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69–74, 2015; Waldman et al., Nat Rev Immunol 20:651–668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named “neoantigen" (Schumacher and Schreiber, Science 348:69–74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely Substitutants, that are produced as a result of aberrant protein translation (Pataskar et al., Nature 603:721–727, 2022).

Main

Catalogues of Substitutant expression across human cancer types, their specificity and association to gene expression signatures remain elusive for the scientific community's access. As a solution, we present ABPEPserver, an online database and analytical platform that can visualize a large-scale tumour proteomics analysis of Substitutant expression across eight tumour types sourced from the CPTAC database (Edwards et al., J Proteome Res 14:2707–2713, 2015). Functionally, ABPEPserver offers the analysis of gene-association signatures of Substitutant peptides, a comparison of enrichment between tumour and tumour-adjacent normal tissues, and a list of peptides that serve as candidates for immunotherapy design. ABPEPserver will significantly enhance the exploration of aberrant protein production in human cancer, as exemplified in a case study.

Conclusion

ABPEPserver is designed on an R SHINY platform to catalogue Substitutant peptides in human cancer. The application is available at https://rhpc.nki.nl/sites/shiny/ABPEP/. The code is available under GNU General public license from GitHub (https://github.com/jasminesmn/ABPEPserver).

Available only for authorised users

Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32:511–7. https://doi.org/10.1093/bioinformatics/btv639.CrossRefPubMed

Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. https://doi.org/10.3389/fimmu.2019.00168.CrossRefPubMedPubMedCentral

Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031-5052.e5026. https://doi.org/10.1016/j.cell.2021.08.023.CrossRefPubMedPubMedCentral

Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2022;40:175–88. https://doi.org/10.1038/s41587-021-01038-8.CrossRefPubMed

Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019;179:964-983.e931. https://doi.org/10.1016/j.cell.2019.10.007.CrossRefPubMedPubMedCentral

da Veiga Leprevost F, Haynes SE, Avtonomov DM, Chang HY, Shanmugam AK, Mellacheruvu D, Kong AT, Nesvizhskii AI. Philosopher: a versatile toolkit for shotgun proteomics data analysis. Nat Methods. 2020;17:869–70. https://doi.org/10.1038/s41592-020-0912-y.CrossRefPubMedPubMedCentral

Dou Y, Kawaler EA, Cui Zhou D, Gritsenko MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Satpathy S, et al. Proteogenomic Characterization of Endometrial Carcinoma. Cell. 2020;180:729-748.e726. https://doi.org/10.1016/j.cell.2020.01.026.CrossRefPubMedPubMedCentral

Edwards NJ, Oberti M, Thangudu RR, Cai S, McGarvey PB, Jacob S, Madhavan S, Ketchum KA. The CPTAC Data Portal: A Resource for Cancer Proteomics Research. J Proteome Res. 2015;14:2707–13. https://doi.org/10.1021/pr501254j.CrossRefPubMed

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019;179:561-577.e522. https://doi.org/10.1016/j.cell.2019.08.052.CrossRefPubMed

10.

Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59. https://doi.org/10.1038/s41568-021-00347-z.CrossRefPubMedPubMedCentral

11.

Huang C, Chen L, Savage SR, Eguez RV, Dou Y, Li Y, da Veiga Leprevost F, Jaehnig EJ, Lei JT, Wen B, et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021;39:361-379.e316. https://doi.org/10.1016/j.ccell.2020.12.007.CrossRefPubMedPubMedCentral

12.

McDermott JE, Arshad OA, Petyuk VA, Fu Y, Gritsenko MA, Clauss TR, Moore RJ, Schepmoes AA, Zhao R, Monroe ME, et al. Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability. Cell Rep Med. 2020;1:100004. https://doi.org/10.1016/j.xcrm.2020.100004.CrossRefPubMedPubMedCentral

13.

Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, Pak HS, Bleijerveld OB, Mordente K, Navarro JM, et al. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature. 2022;603:721–7. https://doi.org/10.1038/s41586-022-04499-2.CrossRefPubMedPubMedCentral

14.

Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021;184:4348-4371.e4340. https://doi.org/10.1016/j.cell.2021.07.016.CrossRefPubMedPubMedCentral

15.

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. https://doi.org/10.1126/science.aaa4971.CrossRefPubMed

16.

Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 2020;124:109821. https://doi.org/10.1016/j.biopha.2020.109821.CrossRefPubMed

17.

Tan X, Li D, Huang P, Jian X, Wan H, Wang G, Li Y, Ouyang J, Lin Y, Xie L. dbPepNeo: a manually curated database for human tumor neoantigen peptides. Database (Oxford). 2020;2020:baaa004. https://doi.org/10.1093/database/baaa004.CrossRefPubMed

18.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013;13:15.PubMedPubMedCentral

19.

Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68. https://doi.org/10.1038/s41577-020-0306-5.CrossRefPubMedPubMedCentral

20.

Wang LB, Karpova A, Gritsenko MA, Kyle JE, Cao S, Li Y, Rykunov D, Colaprico A, Rothstein JH, Hong R, et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell. 2021;39:509-528.e520. https://doi.org/10.1016/j.ccell.2021.01.006.CrossRefPubMedPubMedCentral

21.

Yi X, Liao Y, Wen B, Li K, Dou Y, Savage SR, Zhang B. caAtlas: An immunopeptidome atlas of human cancer. iScience. 2021;24:103107. https://doi.org/10.1016/j.isci.2021.103107.CrossRefPubMedPubMedCentral

22.

Zhang G, Chitkushev L, Olsen LR, Keskin DB, Brusic V. TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes. BMC Bioinformatics. 2021;22:40. https://doi.org/10.1186/s12859-021-03962-7.CrossRefPubMedPubMedCentral

23.

Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol. 2021;12:672356. https://doi.org/10.3389/fimmu.2021.672356.CrossRefPubMedPubMedCentral

Title: ABPEPserver: a web application for documentation and analysis of substitutants
Authors: Abhijeet Pataskar
Jasmine Montenegro Navarro
Reuven Agami
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10970-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Main

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer

Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning

Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer

High SNHG expression may predict a poor lung cancer prognosis based on a meta-analysis

Significance of circulating tumor cells detection in tumor diagnosis and monitoring

ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer